BiPS Medical

BiPS Medical is developing an innovative wearable, wireless device to monitor vital parameters, including blood pressure, blood oxygen saturation (SpO2), respiration rate, and heart rate.

Designed to replace current monitoring of hospitalized patients that is performed by nurses every eight hours, the BiPS device will enable reliable, continuous monitoring of blood pressure and other vital indicators.

BiPS’ Unique System

BiPS Medical is developing an innovative wearable, wireless device to monitor vital parameters, including blood pressure, heart rate, respiration rate, and blood oxygen saturation. The lightweight device is worn on the fingers and regularly analyzes the information obtained from multiple sensors simultaneously.

Designed to replace manual monitoring performed by nurses, the automated monitoring device developed by BiPS will improve patient safety by providing reliable, continuous, real time monitoring of vital indicators. These on-demand measurements will provide early warning signals of patient deterioration.

The BiPS vital sign monitoring device

The BiPS vital sign monitoring device replaces manual monitoring.

The BiPS Opportunity

  • The BiPS device meets the market need for a wearable vital sign monitoring system that includes blood pressure.
  • The Company estimates the U.S. market potential at approximately $720 million.


  • Asi Cohen-Dotan, PhD, CEO: Experienced executive with more than 10 years of scientific, technical, and management experience in the biotech industry; PhD, neurophysiology, Ben-Gurion University of the Negev
  • Nimrod Adi, MD, board member: Director, Intensive Care Department Tel Aviv Sourasky Medical Center; extensive experience in civilian and battlefield trauma, air evacuation of severely injured casualties, and disaster medicine
  • Gil Zoizner, MD, medical manager: ENT surgeon, Kaplan Medical Center; MD, BSc, electronic engineering, Tel Aviv University
  • Jonathan Rubin, PhD., algorithm director: data scientist; PhD, computational neuroscience, BSc, physics and biology, Tel Aviv University

Trendlines’ directors: Steve Rhodes, Barak Singer


Incubated: September 2017
Stage: Technology development
Investors: The Trendlines Group, MOR Research
IP: National phase (United States, Europe, Israel, China, Japan
Achievement: Winner, Trendlines Medtech Open 2017

In the Media

  • Ranked #17: “70 recent reasons to admire Israel on its 70th birthday”
  • Israel21c: ECGs on the move, thanks to Israeli ingenuity

Background & Market

Current bedside monitoring of many hospitalized patients in general care wards is often limited to spot checks by nurses about every eight hours. Checks includes physiologic parameters such as heart rate, blood pressure, respiratory rate, and temperature. Unfortunately, this leaves patients unmonitored the majority of time, and may lead to clinical deterioration of the patient’s condition.

According to an article in the January 2016 Journal of Clinical Nursing (Watkins T, Whisman L, Booker P.), patient deterioration is often preceded by changes in vital signs; and therefore, continuous vital sign surveillance can enhance patient safety.

Current wearable vital sign monitoring devices have numerous drawbacks: cumbersome, lack ability to measure blood pressure, require multiple devices, and may not be accurate enough.

With an estimated 900,000 beds in U.S. hospitals,  the company estimates the U.S. market potential at approximately $720 million, with global potential reaching $1.6 billion.

BiPS logo
Wireless, wearable vital sign monitoring system


Asi Cohen-Dotan, PhD, CEO

Font Resize